Evidence map›Paper›PMID 39917535›Full record

ArticleFrontiers in public health2024

A protocol for mobilising novel finance models for collaborative health promotion and disease prevention initiatives: taking a smart capacitating investment approach in the Invest4Health project.

Joanna Lane, Rhiannon T Edwards, Balázs Babarczy, Holly Whiteley, Vidya Oruganti, Maureen Rutten-van Mölken, Caroline Costongs, Anant R Jani, Sarah Wordsworth, Alison Maassen and 8 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Joanna LaneStichting Health ClusterNET, Amsterdam, Netherlands.
Rhiannon T EdwardsCentre for Health Economics and Medicines Evaluation (CHEME), Bangor University, Bangor, United Kingdom.
Balázs BabarczySyreon Research Institute, Budapest, Hungary.
Holly WhiteleyCentre for Health Economics and Medicines Evaluation (CHEME), Bangor University, Bangor, United Kingdom.
Vidya OrugantiNHH Norwegian School of Economics, Bergen, Norway.
Maureen Rutten-van MölkenErasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands.
Caroline CostongsEuroHealthNet, Brussels, Belgium.
Anant R JaniHeidelberg Institute for Global Health, Heidelberg University, Heidelberg, Germany.
Sarah WordsworthNuffield Department of Population Health, Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, England, United Kingdom.
Alison MaassenEuroHealthNet, Brussels, Belgium.
Apostolos TsiachristasNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, England, United Kingdom.
Jacob DaviesCentre for Health Economics and Medicines Evaluation (CHEME), Bangor University, Bangor, United Kingdom.
Bengt StavenowInnovation Skåne, Lund, Sweden.
Jolanda van VlietDepartment of Future Public Health Services, Kristianstad, Sweden.
Steve WrightStichting Health ClusterNET, Amsterdam, Netherlands.
Lina PapartyteEuroHealthNet, Brussels, Belgium.
Jennifer Catherine CamaradouStichting Health ClusterNET, Amsterdam, Netherlands.
Rositsa Koleva-KolarovaSt Anne's College, University of Oxford, Oxford, England, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The prevalence of preventable non-communicable disease (NCD) underpins the need for a life-course and cross-sectoral approach to population health that is grounded in health promotion and disease prevention. European Union (EU) countries typically spend 6 to 13% of gross domestic product (GDP) on health care, yet less than 3% of this is dedicated to prevention. The extent to which spending in other sectors prevents avoidable ill-health is largely unknown. The lack of fiscal space post-COVID-19 means shifting from models of care built around treatment to those with greater emphasis on prevention will require innovative, evidence-based investment within and between sectors. The term "smart capacitating investment" (SCI) has previously been used to understand how to best boost social infrastructure investment in education, health, transport and housing across the EU. Here we take that idea further by exploring the applicability of SCI to public health financing to improve population health and well-being. Aim: To explore and develop innovative SCI models and tools that enable collaboration and investment across health ecosystems for enhanced health promotion and disease prevention, test them in diverse real-world settings, and create a roadmap for large-scale implementation. Methods: The Invest4Health (I4H) project brings together transdisciplinary expertise in epidemiology, public health, health economics, population science, business management, finance, implementation and social sciences, digital health innovation, and regional health systems. The project consists of eight work packages which span the exploration and conceptualisation of SCI in public health; the characterisation of SCI-compatible business and finance models; piloting and evaluation of these models in four European testbeds (Sweden, Germany, Spain and Wales UK); and exploring the opportunities for sustainable replication and scaling of SCI and future research. Discussion: We present an introduction to the I4H project, the concept of SCI applied to public health, plus key points for discussion internationally.

Indexed as

Health PromotionNoncommunicable DiseasesCOVID-19European UnionHumansInvestmentsPublic Healthhealth economicsinnovative financing mechanismspreventionpublic healthsmart capacitating investment

Identifiers

PMID39917535
PMCPMC11799243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.